About this Research Topic
Tuberculosis (TB) threatens global public health and remains one of the major infectious diseases worldwide. Effective detection and treatment of both drug-sensitive and drug-resistant TB are key challenges in the fight against TB. Currently, only about 50% of the WHO target TB cases are detected and only 30-40% of drug-resistant TB cases are recognized. Treatment success rates are approximately 85% for drug-sensitive TB and drop to only ~60% for multi-drug resistant TB (MDR-TB) on average worldwide. Early detection of TB cases is the first step to providing patients with appropriate treatment. Recognizing drug-resistant TB is more challenging and requires quick and accurate drug susceptibility test (DST) methods. In addition to improved diagnosis and DST, the discovery of new drug targets is crucial for TB control.
This Research Topic focusses on TB and drug-resistance diagnosis, and drug target discovery. It aims to explore novel TB diagnosis methods to quickly find TB cases and recognize drug-resistance. DST for anti-TB drugs is also essential to guide the further diagnosis of drug-resistant TB, how to evaluate and compare them, and establish new DST methods to further guide clinics to use rationally is the other purpose under this topic. At the same time, this Research Topic aims to explore new drug resistance mechanisms and tools to study drug resistance. Finally, it explores new drug targets and tools to study them.
In this Research Topic, we welcome both original articles and review articles on the following subtopics:
1. Novel diagnostic tools for TB, drug-resistant TB or latent TB infection
2. Evaluation and application of diagnostic tools for TB, drug-resistant TB or latent TB infection
3. Resistance mechanism to TB drugs, and comparison and application of different DST methods for drug-resistant TB
4. TB drug target discovery
๐๐ฐ๐ฑ๐ช๐ค ๐๐ฐ๐ฐ๐ณ๐ฅ๐ช๐ฏ๐ข๐ต๐ฐ๐ณ ๐๐ข๐ฒ๐ถ๐ฆ๐ญ ๐๐ช๐ญ๐ญ๐ข๐ณ-๐๐ฆ๐ณ๐ฏ๐ข๐ฏ๐ฅ๐ฆ๐ป ๐ช๐ด ๐ฆ๐ฎ๐ฑ๐ญ๐ฐ๐บ๐ฆ๐ฅ ๐ฃ๐บ ๐๐ฆ๐ฏ๐ฐ๐ฎ๐ฆ ๐๐ฅ๐ฆ๐ฏ๐ต๐ช๐ง๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ต๐ช๐ค๐ด, ๐๐ฆ๐ฏ๐๐ ๐๐ฎ๐ฃ๐ (๐ง๐ณ๐ฐ๐ฎ ๐ต๐ฉ๐ฆ ๐๐ถ๐ต๐ฐ๐ช๐ฎ๐ฎ๐ถ๐ฏ ๐๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ต๐ช๐ฌ๐ข ๐จ๐ณ๐ฐ๐ถ๐ฑ, ๐๐๐ ๐๐ฎ๐ฃ๐). ๐๐ญ๐ญ ๐ฐ๐ต๐ฉ๐ฆ๐ณ ๐๐ฐ๐ฑ๐ช๐ค ๐๐ฅ๐ช๐ต๐ฐ๐ณ๐ด ๐ฅ๐ฆ๐ค๐ญ๐ข๐ณ๐ฆ ๐ฏ๐ฐ ๐ค๐ฐ๐ฎ๐ฑ๐ฆ๐ต๐ช๐ฏ๐จ ๐ช๐ฏ๐ต๐ฆ๐ณ๐ฆ๐ด๐ต๐ด ๐ธ๐ช๐ต๐ฉ ๐ณ๐ฆ๐จ๐ข๐ณ๐ฅ๐ด ๐ต๐ฐ ๐ต๐ฉ๐ฆ ๐๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ ๐๐ฐ๐ฑ๐ช๐ค ๐ด๐ถ๐ฃ๐ซ๐ฆ๐ค๐ต
This Research Topic focusses on TB and drug-resistance diagnosis, and drug target discovery. It aims to explore novel TB diagnosis methods to quickly find TB cases and recognize drug-resistance. DST for anti-TB drugs is also essential to guide the further diagnosis of drug-resistant TB, how to evaluate and compare them, and establish new DST methods to further guide clinics to use rationally is the other purpose under this topic. At the same time, this Research Topic aims to explore new drug resistance mechanisms and tools to study drug resistance. Finally, it explores new drug targets and tools to study them.
In this Research Topic, we welcome both original articles and review articles on the following subtopics:
1. Novel diagnostic tools for TB, drug-resistant TB or latent TB infection
2. Evaluation and application of diagnostic tools for TB, drug-resistant TB or latent TB infection
3. Resistance mechanism to TB drugs, and comparison and application of different DST methods for drug-resistant TB
4. TB drug target discovery
๐๐ฐ๐ฑ๐ช๐ค ๐๐ฐ๐ฐ๐ณ๐ฅ๐ช๐ฏ๐ข๐ต๐ฐ๐ณ ๐๐ข๐ฒ๐ถ๐ฆ๐ญ ๐๐ช๐ญ๐ญ๐ข๐ณ-๐๐ฆ๐ณ๐ฏ๐ข๐ฏ๐ฅ๐ฆ๐ป ๐ช๐ด ๐ฆ๐ฎ๐ฑ๐ญ๐ฐ๐บ๐ฆ๐ฅ ๐ฃ๐บ ๐๐ฆ๐ฏ๐ฐ๐ฎ๐ฆ ๐๐ฅ๐ฆ๐ฏ๐ต๐ช๐ง๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ต๐ช๐ค๐ด, ๐๐ฆ๐ฏ๐๐ ๐๐ฎ๐ฃ๐ (๐ง๐ณ๐ฐ๐ฎ ๐ต๐ฉ๐ฆ ๐๐ถ๐ต๐ฐ๐ช๐ฎ๐ฎ๐ถ๐ฏ ๐๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ต๐ช๐ฌ๐ข ๐จ๐ณ๐ฐ๐ถ๐ฑ, ๐๐๐ ๐๐ฎ๐ฃ๐). ๐๐ญ๐ญ ๐ฐ๐ต๐ฉ๐ฆ๐ณ ๐๐ฐ๐ฑ๐ช๐ค ๐๐ฅ๐ช๐ต๐ฐ๐ณ๐ด ๐ฅ๐ฆ๐ค๐ญ๐ข๐ณ๐ฆ ๐ฏ๐ฐ ๐ค๐ฐ๐ฎ๐ฑ๐ฆ๐ต๐ช๐ฏ๐จ ๐ช๐ฏ๐ต๐ฆ๐ณ๐ฆ๐ด๐ต๐ด ๐ธ๐ช๐ต๐ฉ ๐ณ๐ฆ๐จ๐ข๐ณ๐ฅ๐ด ๐ต๐ฐ ๐ต๐ฉ๐ฆ ๐๐ฆ๐ด๐ฆ๐ข๐ณ๐ค๐ฉ ๐๐ฐ๐ฑ๐ช๐ค ๐ด๐ถ๐ฃ๐ซ๐ฆ๐ค๐ต
Keywords: M. tuberculosis, Drug resistance, Drug susceptibility test, Drug Target Discovery, tuberculosis, diagnosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
